Zubiaur, P.; Benedicto, M.D.; Villapalos-GarcÃa, G.; Navares-Gómez, M.; MejÃa-Abril, G.; Román, M.; MartÃn-VÃlchez, S.; Ochoa, D.; Abad-Santos, F.
SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. J. Pers. Med. 2021, 11, 204.
https://doi.org/10.3390/jpm11030204
AMA Style
Zubiaur P, Benedicto MD, Villapalos-GarcÃa G, Navares-Gómez M, MejÃa-Abril G, Román M, MartÃn-VÃlchez S, Ochoa D, Abad-Santos F.
SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. Journal of Personalized Medicine. 2021; 11(3):204.
https://doi.org/10.3390/jpm11030204
Chicago/Turabian Style
Zubiaur, Pablo, Maria Dolores Benedicto, Gonzalo Villapalos-GarcÃa, Marcos Navares-Gómez, Gina MejÃa-Abril, Manuel Román, Samuel MartÃn-VÃlchez, Dolores Ochoa, and Francisco Abad-Santos.
2021. "SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability" Journal of Personalized Medicine 11, no. 3: 204.
https://doi.org/10.3390/jpm11030204
APA Style
Zubiaur, P., Benedicto, M. D., Villapalos-GarcÃa, G., Navares-Gómez, M., MejÃa-Abril, G., Román, M., MartÃn-VÃlchez, S., Ochoa, D., & Abad-Santos, F.
(2021). SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. Journal of Personalized Medicine, 11(3), 204.
https://doi.org/10.3390/jpm11030204